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INVESTIGATION

Mapping of Variable DNA Methylation Across
Multiple Cell Types Deﬁnes a Dynamic Regulatory
Landscape of the Human Genome
Junchen Gu,*,1 Michael Stevens,*,†,1 Xiaoyun Xing,* Daofeng Li,* Bo Zhang,‡ Jacqueline E. Payton,§
Eugene M. Oltz,§ James N. Jarvis,** Kaiyu Jiang,** Theodore Cicero,†† Joseph F. Costello,‡‡
and Ting Wang*,†,2

*Department of Genetics, Center for Genome Sciences and Systems Biology, ‡Department of Developmental Biology,
§Department of Pathology and Immunology, and ††Department of Psychiatry, Washington University School of Medicine,
St. Louis, Missouri 63110, †Department of Computer Science and Engineering, Washington University in St. Louis, Missouri
63130, **Department of Pediatrics, University of Buffalo, New York 14203, and ‡‡Brain Tumor Research Center, Department
of Neurosurgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143

ABSTRACT DNA methylation is an important epigenetic modiﬁcation involved in many biological processes and
diseases. Many studies have mapped DNA methylation changes associated with embryogenesis, cell differentiation, and cancer at a genome-wide scale. Our understanding of genome-wide DNA methylation changes in a
developmental or disease-related context has been steadily growing. However, the investigation of which CpGs
are variably methylated in different normal cell or tissue types is still limited. Here, we present an in-depth analysis
of 54 single-CpG-resolution DNA methylomes of normal human cell types by integrating high-throughput
sequencing-based methylation data. We found that the ratio of methylated to unmethylated CpGs is
relatively constant regardless of cell type. However, which CpGs made up the unmethylated complement was
cell-type speciﬁc. We categorized the 26,000,000 human autosomal CpGs based on their methylation levels across
multiple cell types to identify variably methylated CpGs and found that 22.6% exhibited variable DNA methylation.
These variably methylated CpGs formed 660,000 variably methylated regions (VMRs), encompassing 11% of the
genome. By integrating a multitude of genomic data, we found that VMRs enrich for histone modiﬁcations
indicative of enhancers, suggesting their role as regulatory elements marking cell type speciﬁcity. VMRs enriched
for transcription factor binding sites in a tissue-dependent manner. Importantly, they enriched for GWAS variants,
suggesting that VMRs could potentially be implicated in disease and complex traits. Taken together, our results
highlight the link between CpG methylation variation, genetic variation, and disease risk for many human cell types.

DNA methylation refers to the addition of a methyl group at the C5
position of cytosine in DNA sequences. Methylation on cytosine can
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occur in different sequence contexts but largely in a CpG dinucleotide
context (Fazzari and Greally 2004). Proper establishment of DNA
methylation early in embryogenesis is vital for normal development
in many organisms (Law and Jacobsen 2010). DNA methylation plays a
pivotal role in genomic imprinting and X-chromosome inactivation,
where methylation of one parental allele suppresses its expression and
leads to monoallelic gene expression (Reik and Lewis 2005). In addition, epigenetic modiﬁcations of the chromatin, including DNA methylation and histone modiﬁcations, orchestrate heritable, cell type- and
developmental stage-speciﬁc gene expression in vertebrates (Robertson
2005; Portela and Esteller 2010).
Since the advent and wide adaptation of next-generation sequencing
in epigenomic studies (Harris et al. 2010), many studies have provided
insights into the functions of DNA methylation at a genome-wide scale.
We now have a catalog of DNA methylomes of many cell types in
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different organisms (Lister et al. 2009, 2013; Shen et al. 2012; Kobayashi
et al. 2013; Zhang et al. 2013; Lee et al. 2015). While the majority of
DNA methylation remains stable once a cell is fully differentiated, DNA
methylation undergoes changes during embryogenesis, cell differentiation, tissue development, aging, and disease progression (Jiang et al.
2013; Meissner et al. 2008; Laurent et al. 2010). Recently, the Roadmap
Epigenomics Consortium generated and analyzed a large number of
reference epigenomic proﬁles including histone modiﬁcations, DNA
accessibility, DNA methylation, and gene expression across a large
number of cell and tissue types. Collectively, the integrated analysis
predicted many elements distal to genes that colocalized with various
histone modiﬁcations, DNA methylation patterns, and relevant transcription factor binding at either open or closed chromatin regions, and
many of them could have gene regulatory functions (Kundaje et al.
2015). In particular, loss of DNA methylation accompanied a gain of
histone modiﬁcations indicative of a poised chromatin state and a gain
of lineage-relevant transcription factor binding during differentiation
of human embryonic stem (ES) cells into different lineages (Tsankov
et al. 2015). Furthermore, in agreement with a similar ﬁnding in mice,
transcription factor binding correlated with a decrease in local DNA
methylation (Stadler et al. 2011). In a study on neural differentiation
from ES cells, different patterns of DNA methylation changes were
observed during consecutive stages of neural progenitors derived from
ES cells (Ziller et al. 2015). Additionally, allelic gene expression was
correlated with promoter DNA methylation in differentiated lineages
from H1 ES cells and certain allelic enhancers showed differential DNA
methylation (Dixon et al. 2015). By analyzing primary breast cell types,
DNA methylation was found to be a stable signature of expressed exons
in luminal and myoepithelial cells (Gascard et al. 2015). During development, it was found that cell origin has a stronger impact than tissue
environment in determining genome-wide DNA methylation patterns
(Lowdon et al. 2014). Lastly, intermediate methylation represented a
conserved signature of gene regulation and exon usage through an
integrative analysis of many cell types (Elliott et al. 2015).
While much effort has been focused on identifying DNA methylation
changes associated with speciﬁc treatment, environmental stimuli, or
with differentiation, we know relatively little about the systematic
patterns of DNA methylation across many cell or tissue types under
physiologically normal conditions. One study analyzed 42 human
Whole Genome Bisulﬁte Sequencing (WGBS) libraries and identiﬁed
21.8% of dynamically regulated autosomal CpGs (Ziller et al. 2013).
Another recent study found that 15.4% of CpGs are strongly differentially methylated among 36 human DNA methylomes (Schultz et al.
2015). While these studies provided valuable resources and insights, the
number of single-CpG-resolution DNA methylomes and the number
of cell types proﬁled are limited. We still do not have a complete picture
of which fraction of the methylome is stable and the extent to which
variable DNA methylation contributes to genome regulation.
In this study, we set out to deﬁne the variably methylated regions
of the human DNA methylome. We combined a large collection of
genome-wide DNA methylation proﬁles spanning multiple cell and
tissue types using two complementary methods, Methylation Dependent ImmunoPrecipitation followed by sequencing (MeDIP-seq) and
Methylation-sensitive Restriction Enzyme digestion followed by sequencing (MRE-seq) (Li et al. 2014). Using a recently developed conditional random ﬁelds-based algorithm, methylCRF (Stevens et al.
2013), we estimated 54 single-CpG-resolution DNA methylomes. Consistent with previous reports, we demonstrated that our DNA methylomes are equal in quality to those proﬁled by Whole Genome Bisulﬁte
Sequencing (WGBS) but much more cost-effective (Stevens et al.
2013; Lee et al. 2015). In-depth analysis of these high-resolution
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DNA methylomes revealed that for each cell type, around 11% of
autosomal CpGs are unmethylated, of which 7% are constantly
unmethylated; overall 22.6% show variable methylation across the
cell types we investigated. Combining the variably methylated
CpGs into regions, we characterized the features of these regions
and their colocalization with various regulatory elements such as
enhancer-associated histone modiﬁcations, transcription factor
binding sites, and disease-associated GWAS (genome-wide association study) variants, and uncovered many important functions
that these dynamic regions might possess.
MATERIALS AND METHODS
Sample collection
All samples were collected from normal individuals and prepared in a
timely fashion to ensure the isolation of high-quality genomic DNA.
Tonsil, endometrium, granulocytes, and monocytes were processed as
previously described (Jarvis et al. 2009; Zhang et al. 2014; Koues et al.
2015). Whole blood was pooled venous blood samples from normal
male individuals. All other samples were processed in the Roadmap
Epigenomics Project and the sample collections have been previously
described (Lowdon et al. 2014; Zhang et al. 2013).
Data processing and methylCRF prediction
MeDIP-seq and MRE-seq data were aligned using BWA (Li and Durbin
2009) against human genome reference hg19 and then processed with
methylCRF to generate single CpG methylation predictions for each of
the 54 samples (Stevens et al. 2013). For the rest of the analysis, only
autosomal CpGs were considered.
CpG categorization
Autosomal CpGs were initially grouped into four biologically motivated
categories based on their distribution of DNA methylation values across
the 54 samples: constitutively unmethylated (U) if all values were below
30%, intermediately methylated (I) if at least 50 libraries had values
between 30–70%, constitutively methylated (M) if all values were above
70%, and variably methylated if there were was a gap of at least 40%
between the third highest and the third lowest methylation values.
The remaining CpGs were then assigned one of the categories using
k-Nearest Neighbors (k-NN) with a k of 4. k-NN was iterated 10 times,
once for each category, to allow convergence.
For enrichment analysis, we merged CpGs within 500 bp of each
other with the same category label to create regions. However, CpGs
crossing blacklisted regions were not merged (The ENCODE Project
Consortium 2012).
For visual inspection on a genome browser, we created two tracks by
segmenting the genome based on CpG methylation patterns across all
54 samples. For the CpG Regions track, we merged CpGs within 500 bp
of each other for each CpG category, in the same way as for enrichment
analysis. For the CpG Regions Extended track, we extended the CpG
Regions in both directions so that the neighboring regions were next to
each other; for regions between CpGs greater than 1000 bp apart, we
created a CpG "desert” state “D”. The “D” state started 50 bp away from
each CpG. Finally, we designated blacklisted regions with “B.”
Genomic distribution of VMRs
Transcription start sites (TSSs) and information about other genomic
features were downloaded from the UCSC genome browser (hg19) (Kent
et al. 2002). The promoter was deﬁned as 2000 bp regions upstream of the
TSS for each gene. Intergenic regions were deﬁned as intervals between
the end of gene bodies and the beginning of promoters. For genomic

distribution analysis, background regions of matching number and size
with VMRs were randomly selected from the human genome.
Determining cell type-speciﬁc hypomethylated VMRs
To call hypomethylated VMRs for each cell type, we ﬁrst calculated the
average DNA methylation levels of all the CpGs located in a VMR for
each sample and then averaged the DNA methylation levels for samples
of the same cell type. We then called a VMR hypomethylated in a cell type
if the average cell type DNA methylation level was below 30%. To ensure
cell type speciﬁcity, we further required that a VMR could only be called
cell type-speciﬁc hypomethylated in no more than three cell types.
TFBS ChIP-seq peak fold enrichment
Transcription factor binding site (TFBS) ChIP-seq narrow peaks data
were downloaded from ENCODE (The ENCODE Project Consortium 2012) and used in the transcription factor peak fold enrichment
analysis. The fold enrichment of TFBS ChIP-seq peaks in VMRs were
calculated using the number of VMRs overlapping ChIP-seq peaks
divided by the number of size-matched randomly selected regions
overlapping the same TFBS ChIP-seq peaks. We used BEDTools
utilities to calculate the intersection (Quinlan and Hall 2010). We
then applied ANOVA with FDR correction to identify tissue typespeciﬁc TFBS peak fold enrichment for each transcription factor.
Transcription factor binding motif enrichment analysis
HOMER was used to search for known transcription factor binding
motifs in hypomethylated VMRs according to the instructions provided
on the website with default parameters (Heinz et al. 2010). The top ﬁve
motifs and corresponding enrichment score p-values were examined
for functional relevance. For tissues with multiple cell types, the median
value of all the p-values from different cells was used to plot the enrichment (Supplemental Material, Figure S5).

hypomethylated VMRs divided by the number of GWAS variants
overlapping size-matched randomly selected regions. For the relevant
GWAS traits enrichment, GWAS traits linked to the identiﬁed variants were used to calculate fold enrichment in VMRs against all the
occurrences in the GWAS catalog by hypergeometric test. Multiple
testing corrections on the hypergeometric p-values were done by the
FDR method for each cell type.
Concordance calculation between methylCRF
and WGBS
Concordances of DNA methylation levels between methylCRF and
WGBS were calculated by counting the number of CpGs with methylation level differences between methylCRF and WGBS less than 25%.
Then, the percentage of CpGs meeting the above criterion was calculated
as the concordance. For WGBS, a minimum read coverage of 10 was
used to select CpGs.
Saturation analysis
We randomly selected n number of samples (n goes from 6–53) and
identiﬁed variably methylated CpGs with 10 iterations, and then the
percentage of variably methylated CpGs were plotted against the number of samples selected.
Data availability and visualization
All the methylCRF prediction custom tracks are displayed using the
WashU Epigenome Browser (Zhou et al. 2011). The read alignment and
processed data for MeDIP-seq and MRE-seq from this publication
have been submitted to the GEO database and assigned the identiﬁer
GSE69894. Relevant variably methylated CpGs and regions data and
browser visualization can be accessed on the website: http://epigenome.
wustl.edu/methylomes.
RESULTS

ChromHMM state enrichment calculation and histone
modiﬁcation ChIP-seq peak calling
Core15-state ChromHMM annotation ﬁles were obtained from the
Roadmap Epigenomics Consortium (Kundaje et al. 2015). The fold
enrichment of ChromHMM states in VMRs were calculated using
the number of VMRs whose centers overlap with a state divided by
the number of size-matched randomly selected regions from the genome overlapping the same chromatin state. The resulting fold enrichment values were log2 transformed and visualized with a heat map.
Histone modiﬁcation ChIP-seq data were downloaded from GEO
(GEO ID: GSE16368). Processed BED ﬁles were used for each ChIPseq dataset. Histone peaks were called using SICER with the default
parameters against hg19 (Zang et al. 2009).
Enhancer analysis and functional enrichment of genes
VISTA enhancer databases were downloaded from the VISTA Enhancer
Browser (Visel et al. 2007). Human positively validated enhancer regions
were used in the analysis and built into a custom browser track. Gene
Ontology enrichment analysis of genes near VMRs was performed using
the GREAT analysis tool (McLean et al. 2010) with the default settings
for deﬁning gene regulatory domains to associate genes to VMRs.
GWAS variants
GWAS variants data were downloaded from the GWAS Catalog of
the National Human Genome Research Institute (Hindorff et al.
2014). The fold enrichment of GWAS variants in hypomethylated
VMRs were calculated using the number of GWAS variants overlapping

Global analysis of 54 methylomes revealed a consistent
proportion of unmethylated CpGs across cell types
coupled with distinct cell-type speciﬁc signatures
In total, we interrogated the DNA methylomes of 54 normal human primary
cell samples (21 cell/tissue types) including, fetal brain, cortex-derived and
ganglionic eminence-derived neurosphere cells, ﬁbroblasts, keratinocytes,
skin melanocytes, luminal epithelial cells, myoepithelial and stem breast cells,
CD4 memory cells, CD4 naïve cells, CD14 monocytes, whole blood, granulocytes, peripheral blood mononuclear cells (PBMC), and endometrium.
For a complete list of cell and tissue types, refer to Table S1.
methylCRF estimates complete DNA methylomes at single-CpGresolution by combining MeDIP-seq and MRE-seq. For all the following
analyses, only autosomal CpGs were considered. We looked at several
metrics of the overall state of methylation in all cell types. The average
DNA methylation levels of all the autosomal CpGs for each cell type
ranged from 77.5–81.7% and displayed small levels of variation among
tissue types and similar levels of methylation among different cell types
of the same tissue type proﬁled in this study (Table S1 and Figure S1A).
For all cell types, the overall distribution of the DNA methylation levels
followed an expected pattern where the majority of CpGs were either
highly methylated (82.4–87.8% of the total CpGs) or unmethylated (9.7–
12.5% of the total CpGs), and a small percentage (2.4–5.6%) of CpGs
were intermediately methylated (Figure 1A, Figure S1B, and Table S1).
Multiple studies support the hypothesis that low DNA methylation
can act as a signature of gene regulation (Stadler et al. 2011; Zhang et al.
2013; Tsankov et al. 2015). We thus thought to identify the potential of
each CpG to have a regulatory role in gene regulation by calculating the

Volume 6 April 2016 |

VMRs Have Regulatory Potentials |

975

Figure 1 Characterization of autosomal CpG methylation patterns across cell types and identiﬁcation of variably methylated CpGs. (A) Density plot of
genome-wide DNA methylation levels of all CpGs for each of the 54 methylCRF (conditional random ﬁelds-based algorithm) predictions. (B) Principal
Component Analysis of average CpG methylation levels for 1 kb genomic windows across 54 methylCRF predictions. Note the clustering of
methylomes by tissue type. (C) Percentage of autosomal CpGs in each category after applying a k-NN (k-Nearest Neighbors) algorithm. M:
constitutively methylated CpGs; I: constitutively intermediately methylated CpGs; U: constitutively unmethylated CpGs; V: variably methylated CpGs.
(D) An example WashU Epigenome Browser view of a genomic region showing different categories of CpGs and the corresponding combined
regions. Note the depletion of methylation around the HOXA7 gene speciﬁcally in skin keratinocytes. Three tracks each for skin ﬁbroblasts,
keratinocytes, and melanocytes; CpG track, CpG categories, and the resulting regions are displayed. In the CpG Categories and CpG Regions tracks,
green indicates constitutively unmethylated CpGs and regions and blue indicates variably methylated CpGs and regions.

lowest possible DNA methylation level for each CpG. We found that
6,769,260 autosomal CpGs (25.4% of total) have their lowest DNA methylation level below 30% (Figure S1C). This ﬁnding suggests that, although
the distribution of DNA methylation maintains the same pattern where
roughly 11% of CpGs are unmethylated (average of the percentage
of unmethylated CpGs among all cell types) for any given cell type,
25.4% of the CpGs could be unmethylated and potentially have
regulatory functions.
Different cell types have distinct methylation signatures. We conﬁrmed that our data supports this notion. By applying the Principle
Component Analysis (PCA) and hierarchical clustering analysis on our
DNA methylomes at 1 kb resolution, we found that the separation and
clustering of samples were deﬁned by tissue types as well as by cell types
(Figure 1B and Figure S1D). In particular, different breast cell type
methylomes had notable similarity to each other whereas blood cell
types were not as closely clustered, reﬂecting tissue type-dependent
variability among samples in their global DNA methylation patterns.
This variability could be due to epigenomic variability within the same
cell type, heterogeneity in cell preparation, or their genetic background.
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The average methylation levels for different genomic features in all
the cell types examined shared the expected pattern of relatively low
average methylation levels in promoter regions compared to gene bodies
(exons and introns) or intergenic regions. Low methylation levels were
particularly evident in high CpG promoters (Figure S1, E and F).
Classiﬁcation of CpGs based on their methylation
patterns across all samples identiﬁed 22.6% of CpGs
being variably methylated
Our data revealed that the overall fractions of methylated or unmethylated CpGs across the 54 methylomes were remarkably similar. However, for any given CpG, its methylation level can be either stable or
variable across the samples. To analyze this characteristic, we categorized
CpGs into biologically informative types. We used simple and conservative notions of constitutively methylated (M), unmethylated (U), and
intermediately methylated (I), as well as variably methylated (V), CpGs
to classify CpGs using 70% and 30% as cutoffs (See Materials and
Methods for details). We were able to assign 21.7 million CpGs based
on these criteria. We then used the categorized CpGs as seed sets for a

k-NN algorithm to classify the remaining CpGs as well as to reﬁne the
category boundaries. This categorization resulted in 22.6% of CpGs
being variably methylated along with 70% of CpGs being constitutively methylated. The fact that 70% of the autosomal CpGs are stably
methylated ($ 70% methylation) in all the 54 samples proﬁled in this
study is in line with the notion that DNA methylation is a stable
epigenetic mark across different human cell types. Of constitutively
methylated CpGs, 61% were located in repeats and 82% of CpGs in
repeats were constitutively methylated (Figure S2, A and B). On the
other hand, the majority (75%) of constitutively unmethylated CpGs
were located in CpG islands, and 74% of all the CpGs in CpG islands
were constitutively unmethylated CpGs (Figure S2, C and D). These
results agree with known patterns of DNA methylation with respect to
repeats and CpG islands. After we categorized each CpG, we segmented the genome into regions of different DNA methylation patterns by combining CpGs of the same category that are within 500 bp
of each other into corresponding regions, which can be viewed on the
Washington University Epigenome Browser (Materials and Methods,
Figure 1D, and Figure S3) (Zhou et al. 2011).
A total of 85% of VMRs were less than 1 kb in length
Many studies have identiﬁed differentially methylated regions and
linked the differential methylation to regulation of gene expression and
cell type differentiation (Zhang et al. 2013; Lowdon et al. 2014). We
thus hypothesized that variably methylated CpGs play a role in regulating gene expression in different cell types and focused our analysis
on CpGs exhibiting variable DNA methylation levels across cell types.
Overall, we deﬁned 6,014,012 CpGs as variably methylated CpGs, and
663,916 regions as VMRs (Table S2).
VMR lengths ranged from 2 bp (solo variably methylated CpG sites)
up to 40 kb (Figure 2A and Figure S4A). The majority of the VMRs were
short as 85% and 96% of VMRs were less than 1 kb and 2 kb in length,
respectively. On average, each VMR contained nine CpGs (Figure S4B).
The majority of the VMRs were located in introns and intergenic
regions with only a small percentage overlapping promoters or exons,
although they tended to overlap with promoters and exons more often
than expected (Figure 2B).
VMRs were distant from TSSs and enriched for TFBSs
Interestingly, the majority (88%) of VMRs were located more than 5 kb
away from annotated transcription start sites (TSSs, Figure 2C), suggesting
they might play a role as distal regulatory elements. Loss of DNA methylation in one germ layer was correlated with binding of lineage-relevant
transcription factors during human ES cell differentiation (Tsankov et al.
2015). Indeed, hypomethylated regions in certain cells might give access to
regulatory elements such as transcription factors or other DNA-binding
proteins to modulate gene expression. To test this hypothesis in the cell
types included in our study, we ﬁrst determined the hypomethylated
VMRs in each cell type (see Materials and Methods, Figure S4C). Then
we integrated publicly available datasets from ENCODE to dissect the
functional potential of these hypomethylated VMRs.
We ﬁrst examined the colocalization between VMRs and TFBSs of
more than 160 transcription factors deﬁned by ChIP-seq peaks (The
ENCODE Project Consortium 2012). A signiﬁcant proportion of VMRs
(36%) overlapped with at least one TFBS peak and this overlap was highly
statistically signiﬁcant (Figure 3A) (Fisher’s exact test, p-value , 2.2e-16).
This evidence points to possible correlation between low DNA methylation and transcription factor binding that might be important for certain transcription factors to direct cellular transcriptional programs. In
addition, 21% of VMRs overlapped with three or more TFBS peaks,
suggesting potential interactions among different transcription factors.

To further pinpoint tissue type-speciﬁc contribution to these observed
colocalizations of transcription factor binding and variable DNA methylation, we calculated the fold enrichment of TFBS peaks over size-matched
randomly selected genomic regions and compared enrichment of transcription factor peaks among tissue types (See Materials and Methods). We
found that the binding of many transcription factors exhibits tissue typespeciﬁc enrichment in hypomethylated VMRs (Figure 3, B–E). There
are several interesting examples of transcription factors known to play
important roles in particular tissue types. For example, FOSL2 is part
of Activator protein 1 (AP-1), which regulates the expression of genes
important in keratinocyte differentiation (Mehic et al. 2005). Its binding
peaks were highly enriched in hypomethylated VMRs of skin (Figure 3C).
Moreover, we found high enrichment of FOSL2 binding peaks located in
VMRs hypomethylated in breast, which supports its role in breast cell
development and carcinogenesis (Schröder et al. 2010). We also found
ESRRA binding peaks highly enriched in hypomethylated VMRs of
breast, where ESRRA is implicated in the etiology of breast cancer (Deblois
et al. 2010). In addition, both NANOG and POU5F1 (OCT4) binding
peaks were more highly enriched in hypomethylated VMRs of brain
(Figure 3E). Both NANOG and POU5F1 are well-known master regulators of pluripotency; speciﬁcally, NANOG is implicated in both normal
neural stem cell self-renewal and tumorigenesis in glioblastoma multiforme (GBM), while OCT4 functions in the differentiation of neural stem
cells into neurons (Po et al. 2010; Zbinden et al. 2010; Deleidi et al. 2011).
In addition to the discovery of many transcription factor binding peaks
enriched in hypomethylated VMRs, we also searched for transcription
factor binding motifs in hypomethylated VMRs and found enrichment of motifs known to play important roles in each particular cell
type (Figure S5). For example, LHX2 is a transcription factor important for neurogenesis in hippocampal development and its motif was
found to be highly enriched in hypomethylated VMRs of various
brain cell types (Subramanian et al. 2011). In many blood cell types,
we found enrichment of motifs of ETS transcription factor family
members such as ETS1 and ERG, which are well-known transcription
factors involved in hematopoietic development (Zhang et al. 1995;
Gallant and Gilkeson 2006). All the evidence supports potential interactions between variable DNA methylation and binding of transcription factors that direct cellular transcriptional machinery.
VMRs colocalized with validated enhancers and
enhancer histone modiﬁcations, and many possessed
enhancer potential
Given the location of the identiﬁed VMRs being distal to TSSs, and the
colocalization of transcription factor binding motifs and assay-identiﬁed
binding sites, we sought to further explore their regulatory potential by
examining their relationships with various histone modiﬁcations assayed
on the same cells. We utilized available ChromHMM annotated chromatin states on each cell type and found enrichment of enhancer or active
TSS-associated chromatin states in hypomethylated VMRs of the majority of cell types (Figure 4A) (Kundaje et al. 2015). In contrast, there was
a depletion of heterochromatin and quiescent states in hypomethylated
VMRs. We called ChIP-seq peaks of histone modiﬁcations for each cell
type and found that up to 87% of the cell type-speciﬁc hypomethylated
VMRs overlapped with enhancer histone modiﬁcation ChIP-seq peaks
represented by H3K4me1 in the same cell type (Figure S6A); the overlaps
are statistically signiﬁcant (Fisher’s exact test, p-value , 8e-10 for all).
We also calculated the average signal density of ChIP-seq data over 10 kb
regions centered around VMRs and found, in general, higher levels of
enhancer or active transcription histone modiﬁcation ChIP-seq signals
centered in the VMRs compared to their ﬂanking sequences (Figure 4,
B–E, and Figure S6, B–E). These results led us to further hypothesize that
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Figure 2 Majority of variably methylated regions (VMRs) are small and distal to transcription start sites (TSSs). (A) Distribution of VMR lengths at
each range. (B) Distribution of VMRs and size matched randomly selected background regions in different genomic features. (C) Distance of VMRs
and background regions to their nearest TSSs.

many of the hypomethylated VMRs that we identiﬁed could possess
potential enhancer activities in different cell types.
To test the enhancer hypothesis, we utilized the VISTA enhancer
project’s validated enhancer data and determined whether our candidate VMRs could have enhancer activities (Visel et al. 2007). Indeed,
we found that a signiﬁcant portion (71%) of positively validated
human VISTA enhancers overlapped with VMRs (Fisher’s exact
test, p-value , 2.2e-16). As an example, VISTA enhancer hs629
was validated to have enhancer activity in mouse dorsal root ganglion and it overlapped with a VMR hypomethylated in fetal brain
samples (Figure 5A). For a complete list of VMRs that overlap with
positively validated VISTA enhancers, refer to Table S3.
To identify the genes and functions that could be potentially
regulated by the hypomethylated VMRs, we analyzed the functional
enrichment for genes near the VMRs in each cell type and found
enrichment of genes whose functions were relevant for that particular cell type. For example, we found many genes near fetal brainspeciﬁc hypomethylated VMRs that encode functions such as
hindbrain development and spinal cord development (Figure 5B,
Figure S7, and Figure S8). We identiﬁed overlaps between several
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VMRs hypomethylated in brain and a positively validated VISTA
enhancer (hs629) near the EVX1 gene, which functions as a determinant of interneuron identity in spinal cord (Region 1 in Figure 5C).
Interestingly, enhancer element hs629 contained a conserved noncoding element that was experimentally validated to have enhancer
activities in interneurons in zebraﬁsh, chick, and rat (Region 2 in
Figure 5C) (Moran-Rivard et al. 2001; Suster et al. 2009). In different
brain cell types, the winged-helix transcription factor FOXD3 has its
promoter unmethylated in all the samples, but has multiple VMRs
surrounding the gene and possibly regulating its expression and function speciﬁcally in brain. FOXD3 is known to play important roles in
establishing the neural crest lineage and in repressing melanogenesis
in either mouse, chicken, or zebraﬁsh (Kos et al. 2001; Stewart et al.
2006; Thomas and Erickson 2009). We found low methylation levels
in brain and high methylation levels in skin melanocytes at these
VMRs (Figure S9). Interestingly, three positively validated VISTA
enhancers were located within a 460 kb region upstream of the FOXD3
gene. In addition, BMP signaling, PAX3, and PAX7 were also found
near hypomethylated VMRs, and they are all part of the gene regulatory interaction networks important for neural crest development

Figure 3 Variably methylated regions (VMRs) enrich for transcription factor binding sites in a tissue-speciﬁc manner. (A) Colocalization between all
VMRs and transcription factor binding sites. Number of transcription factor binding peaks in each VMR were counted and the percentage of VMRs
with 0, 1, 2, or 3 and more transcription factor binding peaks were calculated. Differential fold enrichment of functionally relevant transcription
factor binding peaks in hypomethylated regions for (B) blood, (C) skin and breast, (D) breast, and (E) brain.
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Figure 4 Variably methylated regions (VMRs) enrich for enhancer chromatin states and relevant histone modiﬁcations. (A) Enrichment of 15-state
ChromHMM annotations in cell type-speciﬁc hypomethylated VMRs. Log2 transformed fold enrichment values for each ChromHMM state in each
cell type were calculated and plotted. Replicate ChromHMM states were used for skin melanocytes, ﬁbroblasts, keratinocytes, CD4 naïve cells,
CD4 memory cells, and fetal brain, with replicate number indicated after cell type abbreviation detailed in Table S1. TssA, Active TSS; TssAFlnk,
Flanking active TSS; Enh, Enhancers; TxFlnk, Transcribed at gene 59 and 39; EnhBiv, Bivalent enhancer; EnhG, Genic enhancers; BivFlnk, Flanking
bivalent TSS/Enh; ReprPC, Repressed Polycomb; TssBiv, Bivalent/poised TSS; Tx, Strong transcription; TxWk, Weak transcription; ZNF/Rpts, ZNF
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(Meulemans and Bronner-Fraser 2004). We found that another important neuronal transcription factor OLIG2 might be epigenetically
regulated in brain (Figure S10) (Ligon et al. 2007). Several genes important in keratinocyte development and pathology were found to be
linked to hypomethylation speciﬁcally in keratinocytes. For example,
keratin 2 gene KRT2 were found to be potentially regulated by hypomethylation in several VMRs upstream of KRT2 (Figure S11) (Collin
et al. 1992). In melanocytes, we found that KIT, MITF, PAX3, and
TYR genes underlie functional enrichment, such as developmental
pigmentation and melanocyte differentiation in melanocyte-speciﬁc
hypomethylated VMRs. KIT and MITF are known to be important
components of the melanocyte differentiation molecular machinery, with their individual activities and also functional interactions.
MITF functions as a master regulator in melanocyte development
and its regulation is mediated through transcription factor PAX3.
One of its target genes is TYR, tyrosinase, which encodes the ratelimiting enzyme in melanin synthesis (Figure S12) (Hou et al. 2000;
Levy et al. 2006; Yoshida et al. 2001; Mellgren and Johnson 2004;
Kubic et al. 2008; Yang et al. 2008). All the evidence is consistent
with the hypothesis that hypomethylated VMRs act as enhancers in
speciﬁc cells to regulate nearby functionally related genes, possibly
through transcriptional regulation mechanisms.
Lastly, to test whether cell type-speciﬁc hypomethylated VMRs could
act as enhancers to mediate nearby gene expression, we analyzed gene
expression data of the same samples to see whether we could observe
expression differences correlated with methylation differences in VMRs.
We identiﬁed genes near these VMRs, calculated their expression levels
from RNA-seq data and compared them between two cell types.
We found that between two cell types, genes near hypomethylated
VMRs tend to have statistically signiﬁcantly higher expression levels
(Figure S13). This result supports our hypothesis that hypomethylated VMRs modulate nearby gene expression in speciﬁc cell types,
further supporting their potential role as enhancers.
VMRs enriched for GWAS variants
GWAS have greatly aided our understanding of the genetic basis of many
complex human traits and diseases. It was recently shown that variants
identiﬁed from GWAS are often enriched in regulatory regions (The
ENCODE Project Consortium 2012; Maurano et al. 2012). We hypothesized that VMRs may contain many genomic variants, whose functions could be regulated by epigenetic mechanisms such as DNA
methylation. Thus, we examined the enrichment of genomic variants
from many trait and disease-related GWAS within all possible hypomethylated VMRs deﬁned in each cell type. We found a moderate but
statistically signiﬁcant association between VMRs and GWAS variants.
Overall, VMRs encompassed 2197 published GWAS variants, representing a 1.4-fold enrichment (Fisher’s exact test, p-value , 2.2e-16),
and enrichment of GWAS variants was higher in certain cell types
(Figure 6A). 96.4% of the GWAS variants were located in noncoding
regions highlighting the regulatory potential of noncoding sequences.
Furthermore, 94.3% of GWAS variants located within VMRs were
noncoding. By interrogating the relationship between GWAS and
VMRs, the DNA methylation levels of VMRs provide an epigenetic
annotation of many GWAS variants, which might be useful in understanding the functional relevance of a GWAS variant in a cell type
(Zhou et al. 2015). We calculated the enrichment of GWAS traits linked

to variants in hypomethylated VMRs and found enrichment of
GWAS traits in relevant cell types (Figure 6B). There was signiﬁcant
enrichment of neuronal disease-related traits in different brain cell
types. Interestingly, some immunological function-related traits were
enriched in VMRs hypomethylated in brain, in agreement with recent
ﬁndings concerning the link between the dysfunction of the immune
system and Alzheimer’s disease (Heneka et al. 2015; Matsuda et al.
2015; Gjoneska et al. 2015; Chakrabarty et al. 2015; Guillot-Sestier
et al. 2015). When we looked at individual variants, we found variants
associated with red blood cell traits, white blood cell count, and IgG
glycosylation within blood hypomethylated VMRs; variants associated
with Alzheimer’s disease, schizophrenia, and multiple sclerosis within
brain-related VMRs; and variants associated with systemic sclerosis
and psoriasis within skin-related VMRs. This limited evidence could
be taken to suggest that variants not only tag the disease but may also be
within regulatory sites through which DNA methylation may inﬂuence
phenotypes or disease susceptibility. For a complete list of all the
GWAS variants located in hypomethylated VMRs, refer to Table S4.
To further investigate whether DNA methylation could play a role in
the regulation of these variants, we focused on variants that colocalized
with variably methylated CpGs. Among the 2197 GWAS variants within
VMRs, 30 were in a CpG context. Since DNA methylation levels of
VMRs can be regulatory, the variants could potentially have a direct
impact on gene regulation by inﬂuencing DNA methylation of the CpGs
underlying the variants, providing a mechanistic link between genetic
variants and their associated traits or diseases. For example, rs10499197
was found to be a susceptibility locus for systemic lupus erythematosus
and this CpG was hypomethylated in several blood cell types. The
methylation level of CpGs and VMRs might thus inﬂuence the risk of
disease. For a complete list of all the GWAS variants that in a CpG
context, refer to Table S5.
Comparison with WGBS-based dynamic CpGs
and regions
Ziller et al. (2013) published a seminal paper detailing 42 DNA methylomes using WGBS in normal developmental tissues and cultured cell
lines. The major conclusion from this work was that 21.8% of autosomal CpGs showed dynamic methylation levels that colocalized with
enhancer and other gene regulatory elements. Similarly, Schultz et al.
(2015) recently proﬁled 18 tissue types and found 15.4% of CpGs to be
differentially methylated. Since our study employed different technologies and proﬁled many nonoverlapping sample types, we determined
the extent to which their differentially methylated regions (DMRs)
overlap with our VMRs.
To test the similarity between the methylation levels of our methylCRF prediction and those of WGBS proﬁled on the same cell types, we
calculated their genome-wide concordance (deﬁned as the percentage of
CpGs with a methylation level difference less than 25%) between samples
proﬁled by both Ziller et al. (2013) and this study (See Materials and
Methods). Although the samples were from different sources, the concordance between tested pairs was as high as 85.3%, and methylCRF
predictions of CpG methylation levels were comparable to WGBS
(Table S6). This is consistent with previously reported results
(Stevens et al. 2013; Lee et al. 2015).
We compared the overlap of variably methylated CpGs between ours
and those deﬁned in Ziller et al. (2013) and found that, although their

genes + repeats; Het, Heterochromatin; ReprPCWk, Weak repressed Polycomb; Quies, Quiescent. ChIP-seq signal density RPKM values over a
10 kb region centered on hypomethylated VMRs for (B) cortex derived neurosphere cells, (C) CD8 naïve T cells, (D) breast myoepithelial cells, and
(E) skin keratinocytes. RPKM values at 50 bp resolution were calculated and plotted.
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Figure 5 Genes near variably methylated regions (VMRs) enrich for relevant functions and certain VMRs were experimentally validated as
enhancers. (A) VISTA enhancer element 629 was validated positive by transgenic mouse assay. (B) Gene Ontology term enrichment of genes near
fetal brain hypomethylated VMRs. (C) WashU Epigenome Browser view of the methylation landscape around the EVX1 gene. VISTA enhancer
element 629 overlaps with VMRs downstream of EVX1.

982 |

J. Gu et al.

Figure 6 CpG methylation variation is linked to genetic variation and disease risk in different cells. (A) Fold enrichment of GWAS variants in
hypomethylated VMRs of different cell types. (B) Examples of overrepresentations of functionally relevant GWAS traits in different cells.
Hypergeometric p-values of signiﬁcant enrichment of cell type-relevant GWAS traits in hypomethylated VMRs are shown.
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numbers are similar, 36.1% of variably methylated CpGs identiﬁed by
methylCRF data only account for 38.4% of variably methylated CpGs
identiﬁed by their WGBS data (Figure S14A). The number of VMRs
was smaller than that of DMRs (663,916 vs. 716,087), and 40.4% of
VMRs overlapped with 26.8% of DMRs deﬁned in Ziller et al. (2013)
(Figure S14B). Similarly, 58.2% of VMRs overlapped with 29.9%
of DMRs deﬁned in Schultz et al. (2015) (Figure S14B). Even two
sets of DMRs deﬁned by two WGBS studies showed small overlaps
(Figure S14B). The WGBS DMRs covered more genome sequences
than those of VMRs (315 million bases for VMRs vs. 492 million bases
for Ziller DMRs vs. 384 million bases for Schultz DMRs) (Figure S14C).
When we looked at the set of regions deﬁned in all 3 studies, only up to
27.1% of regions were shared among three studies [27.1% of VMRs,
21.3% of Ziller et al. (2013) DMRs, and 14.3% of Schultz et al. (2015)
DMRs] (Figure S14D). The overlap between VMRs and DMRs was
small in scale, suggesting that the analysis of dynamic DNA methylation has not yet reached saturation, as also suggested in Schultz et al.
(2015). In addition to proﬁling different samples, differences in DNA
methylation proﬁling technology, analysis methods, as well as statistical
cutoffs employed by different studies (the present study; Schultz et al.
2015; Ziller et al. 2013), could have also contributed to our observation
that the identiﬁcation of dynamic DNA methylation has not reached
saturation. One reason for the genome coverage difference comes from
the fact that Ziller et al. (2013) extended single CpG DMRs to 100 bp.
36.6% of DMRs were derived from a single CpG whereas 19.2% of
VMRs were single CpG VMRs (Figure S14E). This difference could
be due to the fact that WGBS relies on a sufﬁcient number of reads to
accurately estimate methylation levels, and some of the single CpG
DMRs could have low coverage and thus lead to inaccurate methylation
calls. Indeed, we found that single CpG DMRs from Ziller et al. (2013)
had signiﬁcantly lower read coverage than the rest of the CpGs covered
by DMRs (Figure S14F, Wilcoxon rank-sum test, p-value , 0.05). If we
only considered the nonsingle-CpG regions in both sets, we observed
almost the same percentage of covered base overlap and a slightly higher
overlap of regions between VMRs and DMRs (Figure S14, G–H). The
discrepancy, not explained by single-CpG regions, is probably due to
different cell types proﬁled in the two studies as only a few cell types were
proﬁled in both, and also the inherent difference between WGBS and
MeDIP-seq and MRE-seq methods used to deﬁne them or both.
By comparing regions identiﬁed uniquely in each study, we found that
they shared similar size and genomic distribution (Figure S15, A–D). VMRspeciﬁc regions had overall higher overlap with promoters and intergenic
regions, and lower overlap with intronic regions (Figure S15D). When we
examined the colocalization with TFBSs, the distribution was very similar across study-speciﬁc regions (Figure S15, E–G) although they all
showed a decrease in the proportion of VMRs harboring potential
TFBSs compared to the complete VMR set (Figure 3A).
Reference methylation dynamics browser track
Using our segmentation, we created a DNA methylation dynamics track
(CpG Regions Extended) for visualization and reference on the Washington University Epigenome Browser (http://epigenomegateway.wustl.
edu/browser/ or Visualization on the companion website, see Materials
and Methods). It provides a summarized source of insight about the
potential activity of genomic regions of interest. This resource should
facilitate the interpretation of and hypothesis generation about genomic
and epigenomic data.
DISCUSSION
In this study, we applied methylCRF to a total of 54 samples spanning
multiple cell and tissue types. We categorized CpGs based on their DNA
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methylation patterns across all the samples examined. A longstanding
observation is that the majority of CpGs in the genome are methylated.
This was conﬁrmed in our analysis, where 70% of the autosomal CpGs
were constitutively methylated ($ 70% CpG methylation) regardless of
the cell type. In contrast, 7.5% of the autosomal CpGs were constitutively unmethylated (# 30% CpG methylation) and, as we have shown,
most of these unmethylated regions are located in CpG islands.
In addition, the majority of the constitutively unmethylated regions
(UMRs) are less than 2 kb. Compared to VMRs, UMRs are much
more enriched in regions close to TSSs, with over a third of them
located in promoter regions (Figure S16).
We identiﬁed 22.6% of the genomic CpGs that show variable DNA
methylation across 54 samples. These CpGs could be functional in
different cell types by varying their methylation levels to inﬂuence the
transcriptional network in a particular cell type. We combined CpGs
into windows and characterized them by looking at their size, distribution, and relationship with various TFBSs, motifs, histone modiﬁcations, enhancer potentials, and GWAS variants. We have compelling
evidence to show that many of the VMRs are distal to known TSSs and
possess enhancer or active transcription histone modiﬁcations. They not
only harbor many known transcription factor binding peaks but also
many functionally relevant transcription factor binding motifs. Many of
these regions have been experimentally validated. With the availability of
more experimental data, more regions are expected to have enhancer
activities in certain cell or tissue types. We found that a considerable
number of GWAS variants overlap with variably methylated CpGs,
suggesting a possible mechanism for the regulation or dis-regulation of
these trait or disease-associated variants.
Our results suggest widespread colocalization between transcription
factor binding and identiﬁed VMRs, even given the currently limited
amount of transcription factor ChIP-seq data. It is tempting to postulate
that those VMRs that did not overlap with current transcription factor
binding events might also harbor regulatory potentials through the
modulation of transcription factor binding.
One striking feature we uncovered is that, regardless of the cell type,
roughly the same percentage of CpGs are being methylated and unmethylated, yet exactly which CpGs in a particular cell type are unmethylated is cell type-dependent (Figure 1A). This discovery suggests that a
cell is able to maintain its epigenome at a default level. In another words,
roughly 11% of the CpGs will be unmethylated in any given cell type
and the epigenome somehow directs unmethylation in CpGs that are
important in cell type speciﬁcation. It would be very interesting to understand the molecular basis and mechanisms of this process in detail.
We have previously shown that methylCRF is highly robust in
predicting single-CpG methylation levels genome-wide with high accuracy in comparison to WGBS but at a much lower cost (Stevens et al.
2013). Here, we present the ﬁrst multiple cell type DNA methylome
analysis using methylCRF predictions. Our study again demonstrates
the power of combining two complimentary techniques for measuring
genome-wide DNA methylation and statistically learning single-CpGresolution DNA methylation levels in multiple different cell types. In
addition, we were able to leverage methylCRF to identify biologically
important regions with variable DNA methylation. Based on our analysis, we speculate that more variably methylated CpGs will be identiﬁed
as more cell types are sequenced and analyzed (Figure S17). We would
argue that the overall ﬁndings are consistent with those derived from
WGBS data and that the results clearly suggest that DNA methylation
plays a role in the regulation of cell or tissue type-speciﬁc gene functions through distal enhancer sites. They highlight the plausible link
between genetic variation and epigenetic regulation. The data generated
and results presented here will be of great interest to the research

community. Our methylation predictions in many cell types could be
utilized to complement other studies in deciphering the epigenomic
landscape of cells. The genome segmentation data and track could
be very useful in bringing the analytical focus on certain important
regions in different studies. The combined use of MeDIP-seq and
MRE-seq through methylCRF continues to be an economical yet
powerful method to generate complete DNA methylomes. Using the
library coverage statistics in the WGBS and our study, we estimate that
a WGBS methylome costs more than 10 times that of a combined
MeDIP-seq and MRE-seq methylome (Table S7). Our methods will
greatly facilitate the application of methods utilizing DNA methylome
data along with other genomic data, such as predicting TFBSs from
DNA methylation data (Xu et al. 2015). With our data and the availability of many more single-CpG-resolution DNA methylome data in
the foreseeable future, we expect the ﬁeld will witness greater insights
gained from integrating data from a complete cell type collection.
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